Merrill Downgrades Biogen to 'Sell'

Analyst Eric Ende says the company's stock price doesn't reflect the significant risks to revenue growth

Merrill Lynch downgraded Biogen (BGEN ) to sell from neutral.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.